Tamara L. Joseph Named General Counsel of TKT
February 15 2005 - 9:31AM
PR Newswire (US)
Tamara L. Joseph Named General Counsel of TKT CAMBRIDGE, Mass.,
Feb. 15 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc.
(NASDAQ:TKTX) today announced that Tamara L. Joseph has joined the
company as Vice President, General Counsel. Ms. Joseph has broad
legal experience in the pharmaceutical industry, including 16 years
of experience in the US, France and Belgium. She joins TKT from
Biogen Idec where she served as Vice President, International
Legal. In her role as General Counsel at TKT, Ms. Joseph will have
responsibility for all its legal and government relations
activities. "I am confident that Tamara's knowledge, judgment and
integrity will be important assets for TKT," said Michael J.
Astrue, President and Chief Executive Officer. "In addition, her
broad experience within the pharmaceutical industry will be
extremely beneficial to us as we continue to bring new products to
market over the next several years." While at Biogen Idec, Ms.
Joseph had overall responsibility for the international legal and
public affairs functions, advising senior management on
international legal issues. She was also an Associate at the law
offices of Morrison & Foerster in New York, Los Angeles and
Brussels, where she handled litigation, intellectual property, and
commercial law matters. Prior to joining Morrison & Foerster,
Ms. Joseph was an Associate at Fried, Frank, Harris, Shriver &
Jacobson in New York. She received a B.A. from Duke University, a
J.D. from the University of Michigan Law School, and LLM degrees
from the College of Europe and from the University of Paris. She is
admitted to practice law in New York, California, England and
Wales. Transkaryotic Therapies, Inc. is a biopharmaceutical company
primarily focused on researching, developing and commercializing
treatments for rare diseases caused by protein deficiencies. Within
this focus, the company markets Replagal(TM), an enzyme replacement
therapy for Fabry disease, and is developing treatments for Hunter
syndrome and Gaucher disease. In addition to its focus on rare
diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney
disease, in the European Union. TKT was founded in 1988 and is
headquartered in Cambridge, Massachusetts, with additional
operations in Europe, Canada and South America. Additional
information about TKT is available on the company's website at
http://www.tktx.com/. This press release contains forward-looking
statements regarding TKT's management structure, as well as
statements containing the words "believes," "anticipates," "plans,"
"expects," "estimates," "intends," "should," "could," "will,"
"may," and similar expressions. There are a number of important
factors that could cause the company's actual results to differ
materially from those indicated by such forward-looking statements,
including, whether TKT will be able to successfully manage its
legal and business development functions, and other factors set
forth under the caption "Certain Factors Which May Affect Future
Results" in the company's Quarterly Report on Form 10- Q for the
quarter ended September 30, 2004, which is on file with the
Securities and Exchange Commission and are incorporated herein by
reference. While the company may elect to update forward-looking
statements at some point in the future, the company specifically
disclaims any obligation to do so, even if its expectations change.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a
trademark of Sanofi-Aventis SA. For More Information Contact:
Justine E. Koenigsberg Senior Director, Corporate Communications
(617) 349-0271 Daniella M. Lutz Corporate Communications Manager
(617) 349-0205 http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/ DATASOURCE: Transkaryotic Therapies,
Inc. CONTACT: Justine E. Koenigsberg, Senior Director, Corporate
Communications, +1-617-349-0271, or Daniella M. Lutz, Corporate
Communications Manager, +1-617-349-0205 both of Transkaryotic
Therapies, Inc. Web site: http://www.tktx.com/ Company News
On-Call: http://www.prnewswire.com/comp/120657.html
Copyright
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jul 2023 to Jul 2024